Healthy, HIV
Conditions
Keywords
HIV, 10-1074, Monoclonal Antibody
Brief summary
This is a phase 1 clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the highly neutralizing anti-HIV-1 monoclonal antibody 10-1074 in HIV-infected and HIV-uninfected individuals.
Detailed description
In preclinical studies carried out in humanized mice and non-human primates, 10-1074 alone or in combination with other neutralizing antibodies led to protection from HIV or simian/human immunodeficiency virus (SHIV) infection and also to sustained suppression of HIV plasma viremia. The aims of this protocol are to evaluate the safety, tolerability and pharmacokinetics profile of 10-1074 in both HIV-infected and HIV-uninfected individuals, and its antiretroviral activity in HIV-infected individuals.
Interventions
BIOLOGICAL3 mg/kg, single dose IV administration of 10-1074
3 mg/kg, single dose IV administration of 10-1074
BIOLOGICAL10 mg/kg, single dose IV administration of 10-1074
10 mg/kg, single dose IV administration of 10-1074
BIOLOGICAL30 mg/kg, single dose IV administration of 10-1074
30 mg/kg, single dose IV administration of 10-1074
Sponsors
University of Cologne
Rockefeller University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Group 1 (HIV-infected) * Males and females, age 18 to 65 * HIV-1 infection confirmed by two independent assays. * Group (1A-1C): HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml by standard assays, or on ART with HIV-1 plasma RNA levels \< 500 copies/ml. HIV-1 RNA levels should be measured on 2 occasions, at least 1 week apart and one measurement must be performed within 49 days prior to enrollment. * Group (1D): HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml by standard assays, measured on 2 occasions, at least 1 week apart. At least one measurement must be performed within 49 days prior to enrollment. * Current CD4 count \> 300 cells/μl. * If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception from 10 days prior to the 10-1074 infusion until the end of the study. Group 2 (HIV-uninfected): * Males and females, age 18 to 65. * Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure. * If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception throughout the study period, as described for the HIV-infected groups above.
Exclusion criteria
Group 1 (HIV-infected): * Have a history of AIDS-defining illness within 1 year prior to enrollment. * History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months. * Any clinically significant acute or chronic medical condition other than HIV infection, that in the opinion of the investigator would preclude participation. * Chronic Hepatitis B or Hepatitis C infection. * Laboratory abnormalities in the parameters listed below: Absolute neutrophil count ≤ 1,000; Hemoglobin ≤10 gm/dL; Platelet count ≤100,000; ALT ≥ 2.0 x ULN; AST ≥ 2.0 x ULN; Total bilirubin ≥ 1.25 x ULN; Creatinine ≥ 1.1 x ULN; Coagulation parameters (PT, PTT or INR) ≥ 1.25 x ULN. * Pregnancy or lactation. * Any vaccination within 14 days prior to 10-1074 administration. * History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions. * Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study. Group 2 (HIV-uninfected): * Confirmed HIV-1 or HIV-2 infection. * History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months. * Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation. * Within the 12 months prior to enrollment, the volunteer has a history of sexually transmitted infection. * Chronic Hepatitis B or Hepatitis C infection. * Laboratory abnormalities in the parameters listed: Absolute neutrophil count ≤ 1,500; Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male; Platelet count ≤ 140,000; Alanine transaminase (ALT) ≥ 1.25 x upper limit of normal (ULN); aspartate transaminase (AST) ≥ 1.25 x ULN; Total bilirubin ≥ 1.25 x ULN; Creatinine ≥ 1.1 x ULN; Coagulation parameters (prothrombin time - PT, partial thromboplastin time - PTT or INR) ≥ 1.25 x ULN. * Pregnancy or lactation. * Any vaccination within 14 days prior to 10-1074 administration. * Receipt of any experimental HIV vaccine in the past. * History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions. * Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 24 weeks after 10-1074 administration |
Secondary
| Measure | Time frame |
|---|---|
| Serum peak concentration of 10-1074, measured in micrograms per ml | 24 hours after 10-1074 administration |
| Serum half-life of 10-1074 expressed in days | 24 Weeks after 10-1074 administration |
| Plasma HIV-1 RNA levels measured in copies/ml | 2 weeks after 10-1074 administration |
Countries
Germany, United States
Outcome results
None listed